A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT05265728 · TERMINATED

Trial details

NCT number: NCT05265728
Sponsor: Biogen
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2022-04-26
Primary completion: 2024-01-18
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.